Vertex expected to do well in Europe this year:
Vertex has given a downbeat sales forecast for 2017, saying negotiations with European health systems are dragging their heels on reimbursing its cystic fibrosis drugs.
Nevertheless, analysts expect the company to be one of the top performing stocks in biotech this year.
The US biotech is one of a raft of life sciences firms hoping to woo investors at the annual JP Morgan pharma conference in San Francisco this week – and despite the slightly disappointing figures, analysts are still backing Vertex because of a strong pipeline aimed at treating subgroups of patients who still have limited treatment options.
Read More
Vertex has given a downbeat sales forecast for 2017, saying negotiations with European health systems are dragging their heels on reimbursing its cystic fibrosis drugs.
Nevertheless, analysts expect the company to be one of the top performing stocks in biotech this year.
The US biotech is one of a raft of life sciences firms hoping to woo investors at the annual JP Morgan pharma conference in San Francisco this week – and despite the slightly disappointing figures, analysts are still backing Vertex because of a strong pipeline aimed at treating subgroups of patients who still have limited treatment options.
Read More